ECU
BMRN icon

Eisler Capital (US)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eisler Capital (US)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-42,641
Closed -$3.51M – 501
2024
Q2 		$3.51M Buy
+42,641
New +$3.55M 0.06% 257

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Eisler Capital (US)'s BMRN Position: Q3 2024 in Review

Eisler Capital (US) sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 42,641 shares — an estimated $3.51M sold.

Eisler Capital (US) first reported a position in BMRN in Q2 2024 and held it in 1 quarter. The position peaked at $3.51M in Q2 2024. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • Eisler Capital (US) reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 42,641 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $3.51M.
  • Eisler Capital (US) first reported a position in BioMarin Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Eisler Capital (US)'s BioMarin Pharmaceuticals position peaked at $3.51M in Q2 2024.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.